Congress Materials - World Conference on Lung Cancer (WCLC 2025)
2025 World Conference on Lung Cancer | Sep 6-9 | Barcelona, Spain
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Depth of Response to Immunotherapy is Associated With Survival Outcomes in Oligoprogressive NSCLC: A Real-World Data Analysis
Katherina C. Chua, Qing Huang, Aisha Hasan, Shu Jin, Stewart Bates, Assieh Saadatpour, Philippe Szapary, Daniel R. Gomez
This poster will be available after Sep 6 2025
Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in EGFRm Advanced NSCLC: The COCOON Global RCT
Byoung Chul Cho, Weimin Li, Alexander I. Spira, Maxwell Sauder, Jill Feldman, Farastuk Bozorgmehr, Milena Mak, Janellen Smith, Pei Jye Voon, Baogang Liu, Panwen Tian, Jiunn-Liang Tan, Cheng-Ta Yang, Jin-Yuan Shih, Nuri Karadurmus, Juan Esteban Cundom, Glaucio Bertollo, Irfan Cicin, Jorge Nieva, Ana Ortega, Pascale Tomasini, Danny Nguyen, Enriqueta Felip, Julia Schuchard, Sean P. Murphy, Bailey G. Anderson, Tonatiuh Romero, Yichuan Xia, Shubin Sheng, Joshua M. Bauml, Parthiv J. Mahadevia, Julian Kam, Mehregan Nematian-Samani, Jairo Simoes, Mark Wildgust, Nicolas Girard
This poster and presentation will be available after Sep 6 2025
FIN-EGFR/CNS: Real World Survival and Patient Characteristics of EGFR Mutated NSCLC Patients With CNS Metastases in Finland
Aija Knuuttila, Monica Ekblom, Lalli Nurmi, Anna Bonin, Eija Heikkilä, Maria Silvoniemi
This poster will be available after Sep 6 2025
First-Line Subcutaneous Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2
Sun Min Lim, Jiunn Liang Tan, Jialei Wang, Luis Paz-Ares, Noriko Yanagitani, Ke-Jing Tang, Damien Urban, Susan C. Scott, Archim Rittmeyer, Sandrine Hiret, Louise Medley, Diego Signorelli, Saugata Das, Ali Alhadab, Miao Wang, Janine Mahoney, Jie Zhang, Sujay Shah, Mahadi Baig, Josiane Mourão Dias
This presentation will be available after Sep 6 2025
Long-Term Survival Outcome After First-Line Osimertinib Monotherapy in Advanced/Metastatic NSCLC: Results From LC-SCRUM-Asia
Hiroki Izumi, Siyi He, Manabu Hiraoka, Yin Wan, Bingcao Wu, Kaname Shiga, Satoru Kitazono, Hiroaki Tsuchiya, Koichi Goto
This poster will be available after Sep 6 2025
Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA
Hidetoshi Hayashi, Benjamin Besse, Se-Hoon Lee, Shun Lu, Danny Nguyen, Sanjay Popat, James Chih-Hsin Yang, Maya Gottfried, Josiane Mourão Dias, Claudio Martin, Mehmet Ali Nahit Sendur, Luis Paz-Ares, Scott Owen, Maria Del Rosario Garcia Campelo, Bo Wang, Seema Sethi, Sujay Shah, Jiarui Zhang, Joshua C. Curtin, Byoung Chul Cho
This poster will be available after Sep 6 2025
PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks (Q4W) Plus Lazertinib in First-line EGFR -Mutated Advanced NSCLC
Susan C. Scott, Josiane Mourão Dias, Baogang Liu, Sun Min Lim, Akira Ono, Vanesa Gutierrez Calderon, Pei Jye Voon, Martin Reck, Nicolas Girard, Samuel Chan, Carlo Genova, Siddhartha Devarakonda, Saugata Das, Ali Alhadab, Miao Wang, Janine Mahoney, Jie Zhang, Sujay Shah, Mahadi Baig, Mor Moskovitz
This presentation will be available after Sep 6 2025
Real-World Characterization of Response Kinetics in Patients With Metastatic NSCLC Receiving First-Line Immunotherapy
Melina E. Marmarelis, Katherina C. Chua, Aisha Hasan, Jorge Da Silva, Stewart Bates, Assieh Saadatpour, Qing Huang
This poster will be available after Sep 6 2025
Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR -Mutated NSCLC
Benjamin Besse, Pascale Tomasini, Byoung Chul Cho, Yongsheng Wang, Dong-Wan Kim, Chien-Chung Lin, Christina S. Baik, Se-Hoon Lee, Shun Lu, Luis Paz-Ares, Rachel E. Sanborn, James Chih-Hsin Yang, Manolo D’Arcangelo, Marcia Cruz-Correa, Sebastian Michels, Joshua C. Curtin, Xuerui Luo, Zacharias Anastasiou, Isabelle Leconte, Zhengyu Jiang, Leonardo Trani, Mahadi Baig, Enriqueta Felip
This presentation will be available after Sep 6 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
